As GLP-1 weight-loss drugs continue to spread across the U.S., researchers are tracking side effects beyond nausea and stomach issues. A new study zeroed in on semaglutide, the active ingredient in Ozempic and Wegovy, and found a higher risk of diagnosed hair loss among users taking it for weight loss. The finding matters because demand for the drug class has surged nationwide in 2024 and 2025.
Study finds a measurable difference in diagnosed hair loss
Researchers reported that patients using semaglutide for weight loss were more likely to receive a medical diagnosis of hair loss than patients using bupropion-naltrexone, another obesity treatment. The study identified a stronger signal in women, according to the published findings released on March 20, 2025.
The analysis focused on medical records and compared diagnosed cases rather than self-reported shedding. That matters because the study measured documented clinical outcomes tied to prescribed treatment, not social media anecdotes or unverified patient posts.
The researchers did not say that semaglutide directly causes every case of hair loss. Instead, the paper stated the study found an association, meaning the data showed a higher observed rate among users in the semaglutide group.
What is confirmed, and what is still unclear for patients
What is confirmed is that the study found a higher relative risk in a real-world patient population in the United States. What is not yet known is the exact biological reason each patient experienced hair loss, or how often shedding reverses after treatment changes.
The study also does not settle whether the medication itself, rapid weight loss, nutritional changes, or stress on the body explains the pattern in every case. Doctors have long noted that significant weight loss can trigger temporary hair shedding in some patients, even outside GLP-1 treatment.
Novo Nordisk, which markets Ozempic and Wegovy, has previously listed common gastrointestinal side effects more prominently than hair loss in public drug materials. The newer study adds data doctors may weigh as prescribing of semaglutide continues across U.S. clinics.
Why researchers are paying closer attention now
The broader context is scale. Ozempic and Wegovy use has expanded sharply in the U.S. as semaglutide became one of the most closely watched prescription drugs in the country during 2024 and 2025.
That growth means even less common side effects can affect a meaningful number of patients when millions of prescriptions are involved. Researchers are now studying a wider range of outcomes because GLP-1 drugs are being used longer term and by more adults seeking obesity treatment.
For patients, the immediate takeaway is practical rather than dramatic. The study adds one more documented risk for clinicians to discuss, but it does not change the fact that treatment decisions still depend on individual health history, weight-loss goals, and physician guidance, based on the findings released March 20, 2025.
